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ABSTRACT 
 
Background: Epidemiological studies suggest that lower total cholesterol (TC) may be 
associated with higher mortality. This study aimed to evaluate whether a decline in total 
cholesterol before death might account for the association of TC with mortality over age 80 
years. 
Methods: Cohort study using primary care electronic health records of 99,758 participants 
aged 80 to 105 years from the UK Clinical Practice Research Datalink (CPRD). Hazard ratios 
(HR) for all-cause mortality were adjusted for age, gender, frailty, comorbidity, blood 
pressure and smoking. Fractional polynomial models were fitted to evaluate longitudinal 
trends in TC before death or end-of-study. Adjusted odds ratios were estimated using 
generalised estimating equations. 
Results: There were 63,630 women and 36,128 men, mean age 86 years, with 29,200 deaths. 
There were 41,164 treated with statins at cohort entry. Compared with TC values of 4.5 to 5.4 
mmol/L, TC values <3.0 mmol/L were associated with higher mortality (statin treated HR 
1.53, 95% confidence interval 1.43 to 1.64, P<0.001; not treated, 1.41, 1.29 to 1.54, 
P<0.001). A secular decline in TC values accelerated in the last two years of life. In the last 
quarter of follow-up, the adjusted odds of TC<3.0 mmol/L for those who died, compared 
with surviving participants, were 3.33 (2.84 to 3.91, P<0.001) for untreated and 1.88 (1.68 to 
2.11, P<0.001) for statin treated participants. 
Conclusions: TC values show a terminal decline in the last years of life. Reverse causation 
may contribute to the association of lower TC with higher mortality in non-randomized 
studies.  
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Abbreviations 
 
BP blood pressure 
CPRD Clinical Practice Research Datalink 
CVD cardiovascular disease 
FP fractional polynomial 
LDL low-density lipoprotein 
TC total cholesterol 
UK United Kingdom 
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BACKGROUND 
A long-term decline in cardiovascular mortality has been associated with increasing 
longevity. People aged more than 80 years now represent the most rapidly increasing sector 
of the population in many high-income countries.(1) Cardiovascular diseases are now more 
frequent at older ages (2) and this poses important questions for cardiovascular disease 
(CVD) prevention strategies for people aged 80 years and over. Hypertension, 
hypercholesterolaemia and smoking are recognized as the leading risk factors for 
cardiovascular diseases but, while smoking cessation may be advocated at any age, the role of 
antihypertensive and cholesterol-lowering therapy at advanced ages is more controversial.  
 
The results of hypertension treatment trials in people aged more than 75 (3,4) or 80 years (5) 
suggest that blood pressure-lowering may be associated with lower mortality and fewer 
cardiovascular events in these age groups. This evidence conflicts with the findings of non-
randomized epidemiological studies which generally show that lower blood pressure (BP) 
values are associated with higher mortality in older people.(6,7) We recently analysed 
systolic BP trajectories in people aged ≥80 years. These analyses revealed that systolic BP 
undergoes a ‘terminal decline’ in the last 24 months of life.(8) This observation suggests that 
the association of lower BP with higher mortality in observational studies may be accounted 
for by reverse causation, if people with lower BP values are generally closer to the end of 
life.(8) A process of terminal decline has been suggested previously in studies of physical and 
cognitive functioning (9-12) but the concept has not previously been applied in studies of 
cardiovascular risk factors. 
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There is strong evidence that cholesterol-lowering with statins is associated with reduced 
mortality and fewer cardiovascular events in primary and secondary prevention populations. 
(13,14) The results of these clinical trials have led to increased prescribing of statins in the 
general population,(15) and statin prescribing is now spilling over into the oldest age 
groups.(16) However, Petersen et al. (17) concluded that there was no evidence from clinical 
trials that cholesterol-lowering treatment was associated with lower mortality in people aged 
more than 80 years. This lack of evidence is concerning because non-randomized studies 
suggest that lower cholesterol levels might be associated with greater mortality in people 
aged more than 80 years.(17) In a review of 12 observational studies, Petersen et al.(17) 
found that the majority of cohort studies find that lower total cholesterol (TC) values are 
associated with higher all-cause mortality, and with higher cholesterol values being 
associated with lower mortality.(18) Data from some studies suggest a U-shaped, or reverse 
J-shaped association, of TC (17,19) or low-density lipoprotein (LDL) cholesterol with all-
cause mortality in the elderly. (20) While some authors suggest that cholesterol may not be a 
risk factor for mortality in old age,(20) other commentators have emphasised the potential for 
reverse causation, if serious illness is associated with declining TC values.(21)  
 
We hypothesized that serum TC values may show a terminal decline in old age, as was 
reported for systolic BP.(8) This study therefore aimed to analyse the association of TC level 
with mortality in people aged 80 years and older. We explored whether serum TC values 
undergo a terminal decline that might in part account for any associations of lower TC values 
with higher mortality. We investigated a large cohort of people aged 80 years and older, with 
stratified sampling to ensure representation of individuals up to 105 years of age.  
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METHODS 
 
Study Design 
A population-based cohort study was conducted in the UK Clinical Practice Research 
Datalink (CPRD). The CPRD is the world’s largest database of primary care electronic health 
records, covering approximately 7% of the UK family practices.(22) The CPRD population is 
considered to be representative of the UK population; the database includes comprehensive 
data for drug prescriptions and diagnoses recorded in primary care, which have been shown 
to be valid in many studies.(22,23)  
 
Study Participants 
The sample was drawn from a complete listing of patients registered in CPRD as sampling 
frame. Stratified sampling by age and study year was employed to ensure adequate 
representation of older ages. Eligible participants were selected from patients aged at least 80 
years old and registered with the UK Clinical Practice Research Datalink (CPRD) at any time 
between 1
st
 January 2001 and the 31
st
 December 2015. For each calendar year from 2001 to 
2015, and for each single year of age from 80 to 105 years, up to a maximum of 1,000 
patients were sampled from the population of patients registered during that year. The 
sampling procedure yielded fewer than 1,000 participants at older ages and some participants 
were sampled in more than one year. The sampling procedure yielded a total of 212,566 
individual participants whose primary care electronic health records were analysed for this 
study. We restricted the analysis to the first five years from cohort entry. 
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Study Measures 
The main measures for the study were statin prescriptions, serum TC and all-cause mortality. 
Statins were considered as a single group based on all statins available for prescription 
between 2001 and 2015. Records for serum TC (mmol/L) were obtained from values 
recorded into primary care electronic records. The mean of all TC records during follow-up 
was included in the analysis using the categories <3.0, 3.0-3.4, 3.5-4.4, 4.5-5.4 and ≥5.5 
mmol/L. All-cause mortality was analysed using the date of death recorded into CPRD. 
Covariates were gender, five-year age group, co-morbidity and frailty category. Co-morbidity 
was determined from analysis of Read medical codes, and where appropriate drug product 
codes, for diabetes mellitus, coronary heart disease, stroke, chronic obstructive pulmonary 
disease, dementia, digestive disorders and musculoskeletal disorders as reported 
previously.(24) Frailty status was assessed using a previously published 36-item electronic 
Frailty Index (eFI).(25) The eFI was devized from the cumulative deficit frailty model with 
the eFI score calculated by the presence or absence of individual deficits as a proportion of 
the total possible.(26) Quantitative traits, including BP, and polypharmacy were omitted from 
the eFI score for this study. Categories of fit, mild, moderate and severe frailty were defined 
following Clegg et al.(25) Participants’ smoking status was evaluated using the most recent 
records into the categories ‘current smoker’, ‘ex-smoker’, ‘non-smoker or not recorded’. 
Systolic BP records were classified into the categories <110, 110-119, 120-139, 140-159 and 
≥160 mm Hg, using the mean of all records during follow-up. 
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Analysis 
The cohort was described by tabulating covariates by TC category and baseline statin 
treatment status. We evaluated the association of TC category with mortality in survival 
analyses. Since the distribution of TC differs substantially according to statin treatment 
status, participants were divided into those treated or not treated with statins at baseline. 
Participants were classified as statin treated if they received one or more statin prescriptions 
within the first 12 months of cohort entry. Kaplan-Meier curves were plotted to present the 
univariate association of TC category with all-cause mortality according to baseline statin 
treatment status. Cox proportional hazards models were fitted, separately for patients treated 
with statins and those not treated with statins. Univariate hazard ratios were estimated; then 
adjustment was made for age, gender and frailty category; finally, comorbidities, systolic BP 
category and smoking status were included. The proportional hazards assumption was 
evaluated using the Schoenfeld residuals. The analysis was conducted using the R program, 
using the ‘survival’ and ‘survminer’ packages.(27)  
 
We evaluated the trajectory of TC over five years’ follow-up, including all TC values 
recorded up to the date of death or end of study. For each month of follow-up, we estimated 
the mean TC value for each participant. Data for each participant month were classified as 
statin treated if participants had received a statin prescription in the previous 90 days. We 
used scatter plots to compare changes in mean TC values over time for participants who died 
by the end of the study and participants who remained alive. Data were smoothed with 
moving averages using three successive observations. We fitted second-order fractional 
polynomial (FP) models to evaluate trends in TC over time before death or end of study using 
mean TC values for each participant month as observations. (28) The month from five years 
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before death to the end of study was included in FP models as a continuous predictor with 
values ranging from -60 to -1. FP models were adjusted for age, gender and frailty category. 
Models were fitted using the ‘mfp’ package in the R program. (28) Predicted values and their 
95% confidence intervals were estimated and overlaid on the scatterplot of empirical values. 
The relative odds of TC <3.0 mmol/L for deceased participants, compared with those who 
were alive at end of study, were estimated using the method of generalised estimating 
equations. Odds ratios were adjusted for age, gender and frailty category and clustering by 
participant. 
 
RESULTS 
 
The initial cohort comprised 212,566 participants of whom 99,758 (47%) had one or more 
TC records within five years of entry to the study. A flowchart is shown in Supplementary 
Figure 1. The remaining analyses include 99,758 participants including 36,128 (36%) men 
and 63,630 (64%) women aged 80 years or older. There were 58,594 patients not treated with 
statins and 41,164 patients treated with statins. There were 29,200 deaths during follow-up 
including 18,052 in non-users of statins and 11,148 in statin-users. 
 
Table 1 presents the characteristics of participants divided by serum TC level. TC decreased 
with age, but there was only one year difference in age between highest and lowest 
categories. In the highest TC category, 82% of participants were women, while only 34% of 
the lowest TC category were female. Lower TC values were associated with greater frailty, 
55% of participants with TC less than 3.0 mmol/L had moderate or severe frailty, compared 
with 30% of those with TC ≥5.5 mmol/L. Participants with secondary prevention indications, 
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including diabetes mellitus, coronary heart disease and stroke were more highly represented 
in the lower TC categories, while trends were less marked or absent for other comorbidities. 
Low TC values were also strongly associated with lower systolic BP category and stronger 
association with previous smoking. 
 
Table 2 shows the distribution of covariates according to statin treatment status. As expected, 
statin treated participants had generally lower TC values. Statin treated participants also 
tended to be younger, were more frequently male, with greater levels of frailty and more 
frequently had comorbidities, especially secondary prevention indications including diabetes, 
coronary heart disease and stroke. 
 
Figure 1 presents Kaplan-Meier curves by TC category for participants who were treated or 
not treated with statins. During the five- year period of follow-up, there was a graded 
association of lower TC category with higher mortality. Participants with TC values <3.0 or 
3.0-3.4 had higher mortality than participants with TC values of 4.5-5.4 or ≥5.5 mmol/L. This 
pattern of association was generally similar in statin treated or untreated participants. 
 
Table 3 presents hazards ratios from the proportional hazards models. In univariate analyses, 
using TC values of 4.5-5.4 mmol/L as reference, there was a graded association of lower TC 
values with greater mortality. For participants with TC <3.0 mmol/L, the relative hazard was 
approximately two times higher than reference for both statin treated and untreated 
participants. Adjustment for age, gender and frailty category reduced hazard ratios, but the 
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graded negative association of TC category with higher mortality remained. After further 
adjustment for comorbidities, systolic BP and smoking category, the adjusted hazard ratio for 
the lowest TC category was 1.41 (95% confidence interval 1.29 to 1.54) in participants not 
treated with statins and 1.53 (1.43 to 1.64) in participants treated with statins. In univariate 
analyses, there was evidence that the proportional hazards assumption for TC category did 
not hold either for statin treated (chi-square 33.8, P<0.001) or untreated participants (chi-
square 26.2, P<0.001). For adjusted analyses in participants treated with statins, there was no 
evidence that the proportional hazards assumption was invalid, except for systolic BP 
category. For participants not treated with statins, there was evidence that the proportional 
hazards assumption did not hold for frailty category, systolic BP category, comorbidities of 
diabetes and cancer, with less strong evidence for non-proportionality with respect to TC 
category. The reported hazard ratios can be interpreted as the average effect over the duration 
of follow-up. 
There were 262,518 participant months with TC values recorded. The median number of 
participants contributing data per month was 4,446 (range 1,934 to 6,480). There was a 
median of two months per participant with TC values recorded (range one to 34). Figure 2 
presents a plot of TC values by month from 60 months to one month before death or end of 
study. Points represent the mean of TC values recorded in that month, smoothed as moving 
averages; shaded bands represent the 95% confidence limits for predicted values from the 
multiple fractional polynomial model. There is generally good agreement between empirical 
and predicted estimates. Data for participants treated with statins show generally lower TC 
values than for participants not treated with statins. In participants who did not die during 
follow-up, shown in blue, there is a declining secular trend in TC values over time but the 
data points appear to fit a linear trend. Participants who died during the five-year study period 
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show lower TC values throughout the period. However, data points fit a declining curve with 
TC values showing an accelerated decline during the final 24 months of life. Supplementary 
Table 1 presents the transformations and coefficients selected for the multiple FP models. 
Cubic terms were selected as best fit to data for participants who died, while square or 
inverse square terms were selected for participants who remained alive during the study 
period.  
In the last three months of life, in participants not treated with statins at baseline, 11.3% of 
women and 23.3% of men had TC values <3.0 mmol/L compared with 3.6% of women and 
8.0% of men who did not die (Supplementary Table 2 and Supplementary Figure 2). In the 
last quarter of follow-up, the adjusted relative odds of TC<3.0 mmol/L for those who died, 
compared with surviving participants, were 3.33 (2.84 to 3.91, P<0.001) for untreated and 
1.88 (1.68 to 2.11, P<0.001) for statin treated participants. 
 
DISCUSSION 
Main findings 
These non-randomized data confirm an association of lower TC values with greater mortality 
in people aged more than 80 years. There was a strong univariate association of TC values 
<3.0 mmol/L or 3.0-3.4 mmol/L with increased mortality. This association was partly 
accounted for by confounding with frailty, comorbidity, BP and smoking but even in adjusted 
analyses there was evidence that mortality might be 40-50% higher in those with TC<3.0 
mmol/L compared with 4.5-5.4 mmol/L as reference. We noted that there was evidence that 
the proportional hazards assumption did not hold in certain analyses. This might suggest that 
the significance of low TC values might vary over time before death. Longitudinal analysis of 
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TC values in relation to date of death suggested that there is a terminal decline in TC values 
in the last 12-24 months of life, as we have reported previously for systolic BP.(8) This 
observation raises the possibility that the association between low TC and mortality might be 
accounted for in part by reverse causation because patients with lower TC values may be 
closer, on average, to the end-of-life. This might account for the lack of consistency between 
observational studies and randomized controlled trials in the association of TC with 
mortality. In randomized trials, participants in each trial will on average have a similar 
expected proximity to death, which may not be the case when comparison groups are 
assembled in observational studies. However, we caution that there are several potential 
explanation for the association of lower cholesterol with proximity to death with some writers 
associating elevated cholesterol with protection against infection(29) and improved immune 
defences. (30) 
 
Comparison with other studies 
Petersen et al.(17) noted that most outcome trials of lipid-lowering therapy have been 
conducted in patients who are considerably younger than 80 years. (31) However, meta-
analyses of data for participants aged ≥65 years suggest statin therapy may reduce mortality 
when used for primary(32) or secondary prevention.(33) Petersen et al. (17) conducted a 
systematic review and found consistent evidence from non-randomized studies that lower TC 
values are associated with higher mortality in people aged more than 80 years. The same 
pattern of association has been reported for LDL-cholesterol values,(20) and for older people 
with type 2 diabetes mellitus (34) and heart failure.(35) Kalantar-Zadeh et al.(35) referred to 
the association of elevated cardiovascular risk factors with lower mortality as ‘reverse 
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epidemiology’ and drew attention to the particular relevance of this phenomenon for very old 
people.(36) The mechanisms underlying this effect may include deteriorating organ 
functioning, diminishing nutritional status, as well as inflammatory processes.(21,35-37) 
Higher TC values have also been associated with recovery from disability after illness. (38) 
The present data underline the importance of a longitudinal perspective because TC values 
may not track at consistent levels over time, but rather enter a phase of more accelerated 
decline some months before the end-of-life. This observation suggests reverse causation as a 
plausible explanation for the association of lower TC values with higher mortality. The 
observation also raises questions concerning the appropriateness of lipid-lowering therapy at 
the end-of-life. 
 
Strengths and limitations  
The study had the strengths of data from a large cohort of individuals aged 80 years and over 
with stratified sampling ensuring representation up to the age of 105 years, drawing on a 
nationally representative data source in the UK. Mortality was comprehensively ascertained 
from dates of death recorded into primary care records. We classified patients’ frailty level 
according to an established measure of frailty but this relied on medical diagnoses coded into 
electronic health records, consistent with a deficit accumulation model of frailty.(25,39) This 
approach may not always be consistent with assessment of a frail phenotype characterized by 
weight loss, weakness and low energy expenditure, though the two approaches are correlated 
at population level.(40) TC values were those recorded in clinical practice and we 
acknowledge that these suffer from several limitations. Fewer than half of all eligible 
participants had TC values recorded; cholesterol measurement methods were not standardized 
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across the cohort; data for cholesterol sub-fractions were generally not available; and 
measurement occasions were those selected by clinicians. Decisions to perform cholesterol 
tests may have been associated with confounding by indication if investigations were ordered 
when patients presented with illness. Consequently, patients with non-measured cholesterol 
values might differ from those with values recorded, consistent with a ‘missing not at 
random’ mechanism. The direction of any possible bias might be difficult to anticipate. We 
acknowledge that TC values were sparsely recorded during follow-up, with generally fewer 
than 5% of participants contributing data in each month of follow-up, with a median of two 
TC values per participant. Consequently, further prospective studies will be needed to 
confirm these observations. For survival analyses we divided patients into two groups 
according to baseline statin treatment. We acknowledge that treatment inception and 
discontinuation may have occurred during follow-up (41) but the focus of our analysis was on 
TC levels and not on statin treatment. When TC trajectories were evaluated, statin utilisation 
was evaluated for each period of follow-up. We acknowledge that there may be relevant 
variables that were not available for analysis. Patients’ social status, social networks and 
income may be associated with statin prescribing and with mortality but we did not have data 
available for analysis. We also acknowledge that the e-frailty index is based on a cumulative 
deficit model of frailty. It includes common comorbidities including diabetes, heart disease, 
stroke and respiratory disease using distinct case definitions. Adjustment for comorbidity in 
addition to frailty could lead to problems of over-adjustment. However, comparison of 
estimates from models adjusted for frailty or frailty and comorbidity shows no difference in 
interpretation, though the generally lower estimates form the latter are consistent with 
reduced residual confounding. 
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Conclusions 
These data from a large population-based cohort of adults aged from 80 to 105 years, confirm 
an association of low TC values with all-cause mortality. Longitudinal analysis of TC records 
reveals that TC values show a declining secular trend but there is evidence of an accelerated 
decline in TC values in the last 12-24 months of life, which is not observed in participants 
who do not die. The observation of a terminal decline in TC values suggests that reverse 
causation may in part account for the association of mortality with low TC in non-
randomized studies.  
 
These findings have relevance for both researchers and clinicians. These results draw the 
attention of researchers to the importance of studying longitudinal changes in physiological 
and pathophysiological measures in very old people. Such changes may be of prognostic 
importance and might indicate the need and potential for future intervention. In clinical 
contexts, these observations help to explain why randomized trial estimates may differ from 
those derived from observational studies, providing clinicians with reassurance that non-
randomized associations of lower TC with higher mortality might not be regarded as causal, 
but instead accounted for by reverse causation.  
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Table 1: Baseline characteristics of participants by total cholesterol category. Figures are frequencies (column percent) 
  Total Cholesterol (mmol/L)  
  <3.0 3.0-3.4 3.5-4.4 4.5-5.4 ≥5.5 P value 
        
Age (years) Mean (SD) 87 (5) 86 (5) 86 (5) 86 (5) 86 (5) <0.001 
       
Gender Men 2,636 (66) 3,688 (60) 14,381 (47) 10,823 (33) 4,600 (18) <0.001 
 Women 1,341 (34) 2,475 (40) 16,464 (53) 21,883 (67) 21,467 (82)  
        
Frailty Fit 439 (11) 794 (13) 5,191 (17) 7,470 (23) 7,518 (29) <0.001 
 Mild 1,377 (35) 2,223 (36) 11,783 (38) 13,183 (40) 10,554 (40) <0.001 
 Moderate 1,301 (33) 1,984 (32) 9,352 (30) 8,507 (26) 5,808 (22) <0.001 
 Severe 860 (22) 1,162 (19) 4,519 (15) 3,546 (11) 2,187 (8) <0.001 
        
Comorbidity DM 1,431 (36) 1,951 (32) 7,971 (26) 5,772 (18) 2,627 (10) <0.001 
 CHD 2,010 (51) 2,884 (47) 12,199 (40) 9,532 (29) 5,182 (20) <0.001 
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 Stroke 799 (20) 1,110 (18) 4,310 (14) 3,417 (10) 1,870 (7) <0.001 
 COPD 781 (20) 1,196 (19) 6,125 (20) 6,309 (19) 4,866 (19) 0.003 
Dementia 386 (10) 602 (10) 2,557 (8) 2,612 (8) 1,850 (7) <0.001 
 Cancer 994 (25) 1,403 (23) 7,099 (23) 6,894 (21) 5,011 (19) <0.001 
 Digestive 2,682 (67) 4,074 (66) 19,557 (63) 19,616 (60) 14,747 (57) <0.001 
 MSK 3,018 (76) 4,765 (77) 24,145 (78) 25,193 (77) 20,002 (77) 0.043 
        
Smoking status Ex-smoker 1,602 (40) 2,496 (40) 11,801 (38) 11,025 (34) 7,624 (29) <0.001 
Current smoker 196 (5) 341 (6) 1,700 (6) 1,853 (6) 1,316 (5) 0.281 
        
Systolic BP 
category 
(mm Hg) 
<110 339 (9) 384 (6) 1,185 (4) 846 (3) 448 (2) <0.001 
110-119 628 (16) 762 (12) 2,814 (9) 2,089 (6) 1,169 (4)  
120-139 1,930 (49) 3,107 (50) 14,813 (48) 13,928 (43) 9,144 (35)  
 140-159 821 (21) 1,534 (25) 9,855 (32) 12,530 (38) 11,473 (44)  
 ≥160 133 (3) 216 (4) 1,595 (5) 2,734 (8) 3,330 (13)  
 Not known 126 (3) 160 (3) 583 (2) 579 (2) 503 (2)  
        
Downloaded from https://academic.oup.com/biomedgerontology/article-abstract/doi/10.1093/gerona/glx184/4259390/Trajectory-of-Total-Cholesterol-in-The-Last-Years
by King's College London user
on 28 September 2017
Ac
ce
pte
d M
an
us
cri
pt
 
26 
 
Table 2: Characteristics of participants by baseline statin treatment status. Figures are frequencies (column 
percents) 
 
  No statins Statins P value 
  (58,594) (41,164)  
     
Age (years) Mean (SD)    
     
Gender Men 19,328 (33) 16,800 (41) <0.001 
 Women 39,266 (67) 24,364 (59)  
     
Frailty Fit 15,936 (27) 5,476 (13) <0.001 
 Mild 23,423 (40) 15,697 (38) <0.001 
 Moderate 13,735 (23) 13,217 (32) <0.001 
 Severe 5,500 (9) 6,774 (16) <0.001 
     
Comorbidity DM 8,208 (14) 11,544 (28) <0.001 
 CHD 12,292 (21) 19,515 (47) <0.001 
 Stroke 4,888 (8) 6,618 (16) <0.001 
 COPD 10,874 (19) 8,403 (20) <0.001 
Dementia 4,648 (8) 3,359 (8) 0.193 
 Cancer 12,171 (21) 9,230 (22) <0.001 
 Digestive 33,983 (58) 26,693 (65) <0.001 
 Musculoskeletal 43,890 (75) 33,233 (81) <0.001 
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Smoking status Ex-smoker 18,572 (32) 15,976 (39) <0.001 
Current smoker 3,142 (5) 2,264 (5) 0.345 
     
Systolic BP 
category 
<110 1,760 (3) 1,442 (4) <0.001 
110-119 3,896 (7) 3,566 (9)  
 120-139 22,963 (39) 19,959 (48)  
 140-159 22,729 (39) 13,484 (33)  
 ≥160 5,924 (10) 2,084 (5)  
 Not known 1,322 (2) 629 (2)  
     
Total 
Cholesterol 
(mmol/L) 
<3.0 979 (2) 2,998 (7) <0.001 
3.0-3.4 1,655 (3) 4,508 (11)  
3.5-4.4 12,521 (21) 18,324 (45)  
 4.5-5.4 21,454 (37) 11,252 (27)  
 ≥5.5 21,985 (38) 4,082 (10)  
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Table 3: Relative hazards of all-cause mortality by total cholesterol category and baseline statin treatment in men and women aged 80 years 
and older. 
 
Total 
Cholesterol 
(mmol/L) 
N Deaths Univariate 
Adjusted for age, gender and 
frailty 
Adjusted for age, gender, frailty, 
comorbidity, systolic BP and smoking 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
            
No statins            
<3.0 979 577 1.97  1.81 to 2.15 <0.001 1.66 1.53 to 1.81 <0.001 1.41 1.29 to 1.54 <0.001 
3.0-3.4 1,655 853 1.46 1.36 to 1.57 <0.001 1.31 1.21 to 1.40 <0.001 1.14 1.06 to 1.22 <0.001 
3.5-4.4 12,521 5,018 1.17 1.13 to 1.22 <0.001 1.10 1.06 to 1.14 <0.001 1.04 1.00 to 1.08 0.027 
4.5-5.4 21,454 6,506 Ref.   Ref.   Ref.   
>5.5 21,985 5,098 0.82 0.79 to 0.85 <0.001 0.89 0.86 to 0.92 <0.001 0.95 0.92 to 0.99 0.013 
            
Statins            
<3.0 2,998 1,322 2.19 2.05 to 2.34 <0.001 1.86 1.74 to 1.99 <0.001 1.53 1.43 to 1.64 <0.001 
3.0-3.4 4,508 1,513 1.52 1.43 to 1.62 <0.001 1.36 1.27 to 1.45 <0.001 1.19 1.12 to 1.27 <0.001 
3.5-4.4 18,324 4,900 1.16 1.11 to 1.22 <0.001 1.10 1.04 to 1.15 <0.001 1.05 1.00 to 1.10 0.076 
4.5-5.4 11,252 2,536 Ref.   Ref.   Ref.   
>5.5 4,082 877 1.03 0.95 to 1.11 0.441 1.05 0.97 to 1.14 0.200 1.09 1.01 to 1.18 0.022 
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CI, confidence interval; HR, hazard ratio; N, number of participants
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Legend for Figure 1: Kaplan-Meier curves by total cholesterol level for patients treated and not 
treated with statins. TC, total cholesterol. 
3 
Legend for Figure 2: Trajectory of total cholesterol during 60 months before death (red) or end 
of study (blue) in participants treated or not treated with statins. Data points are mean total 
cholesterol by month; blue squares, alive at end of study; red circles, died. Shaded areas 
represent 95% confidence intervals for predictions from multiple fractional polynomial model 
adjusted for age, gender and frailty category.  
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Figure 1 
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Figure 2 
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